… prophylactic vaccine comprised of a mixture of virus-like particles derived from the L1 capsid
proteins of human papillomavirus (HPV) types 16 and 18 formulated with the AS04 adjuvant …

… human papillomavirus vaccination was used as an adjuvant … studies using human
papillomavirus vaccination as adjuvant … evaluation of adjuvant human papillomavirus vaccination …

… -16/18 AS04-adjuvanted vaccine was examined in preteenage/… Thus, the HPV-16/18
AS04-adjuvanted vaccine was gen… The AS04adjuvanted vaccine provides significant protection for …

… the human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine CervarixTM
(… HPV-16/18 vaccine and 13,811 who received one of three controls [Al(OH)3 or hepatitis A …

… Human papillomavirus (HPV) vaccines are now licensed in more than 100 countries.
National and regional immunisation programmes aimed at young adolescent girls have been …

… Prophylactic human papillomavirus (HPV) vaccines have to … of the HPV-16/18 AS04-adjuvanted
vaccine up to 6.4 years. … of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years. …

… -16/18 AS04-adjuvanted vaccine in boys in this study were … The HPV-16/18 AS04-adjuvanted
vaccine schedule was the … -16/18 AS04-adjuvanted vaccine in boys in this study compared …

… further data on vaccine efficacy (VE) against HPV‐16/18 in the total vaccinated cohort
including women who may have been exposed to HPV‐16/18 infection before vaccination. In …

… human papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer
can also be vaccinated. We … of the HPV 16/18 AS04-adjuvanted vaccine in adult women. …

Background Although the risk of human papillomavirus (HPV) infection is greatest in young
women, women older than 25 years remain at risk. We present data from the VIVIANE study …